PortalPublikationenComparison of Haploidentical Bone Marrow versus Matched Unre...

Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia

Standard

Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. / Nagler, Arnon; Labopin, Myriam; Dholaria, Bhagirathbhai; Angelucci, Emanuele; Afanasyev, Boris; Cornelissen, Jan J; Sica, Simona; Meijer, Ellen; Ciceri, Fabio; Van Gorkom, Gwendolyn; Kröger, Nicolaus; Martin, Hans; Pioltelli, Pietro; Risitano, Antonio; Canaani, Jonathan; Savani, Bipin N; Sanz, Jaime; Mohty, Mohamad.

in: CLIN CANCER RES, Jahrgang 27, Nr. 3, 01.02.2021, S. 843-851.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Nagler, A, Labopin, M, Dholaria, B, Angelucci, E, Afanasyev, B, Cornelissen, JJ, Sica, S, Meijer, E, Ciceri, F, Van Gorkom, G, Kröger, N, Martin, H, Pioltelli, P, Risitano, A, Canaani, J, Savani, BN, Sanz, J & Mohty, M 2021, 'Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia', CLIN CANCER RES, Jg. 27, Nr. 3, S. 843-851. https://doi.org/10.1158/1078-0432.CCR-20-2809

APA

Nagler, A., Labopin, M., Dholaria, B., Angelucci, E., Afanasyev, B., Cornelissen, J. J., Sica, S., Meijer, E., Ciceri, F., Van Gorkom, G., Kröger, N., Martin, H., Pioltelli, P., Risitano, A., Canaani, J., Savani, B. N., Sanz, J., & Mohty, M. (2021). Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. CLIN CANCER RES, 27(3), 843-851. https://doi.org/10.1158/1078-0432.CCR-20-2809

Vancouver

Nagler A, Labopin M, Dholaria B, Angelucci E, Afanasyev B, Cornelissen JJ et al. Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. CLIN CANCER RES. 2021 Feb 1;27(3):843-851. https://doi.org/10.1158/1078-0432.CCR-20-2809

Bibtex

@article{b689561adf664448b6c4ed462c3c40bb,
title = "Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia",
abstract = "PURPOSE: Posttransplant cyclophosphamide (PTCy) is increasingly being utilized as a principle GvHD prophylaxis strategy in allogeneic hematopoietic cell transplantation (allo-HCT). A haploidentical (haplo) or matched unrelated donor (UD) is a valid option in the absence of a matched related donor.EXPERIMENTAL DESIGN: We compared the outcomes of patients with acute leukemia who underwent haplo bone marrow (haplo-BM, N = 401) versus UD mobilized peripheral blood stem cells (UD-PB, N = 192) transplantation in the setting of PTCy.RESULTS: The median follow-up duration was 36 months in the haplo-BM group and 16.6 months in the UD-PB group, respectively (P < 0.01). Myeloablative conditioning was used in 64.6% and 42.7% of haplo-BM and UD-PB patients, respectively (P < 0.01). Cumulative incidence of neutrophil engraftment at day 30 was 87% in haplo-BM versus 94% in UD-PB, respectively (P = 0.21). In the multivariate analysis, the risk of grade 2-4 acute GvHD (HR = 0.53, P = 0.01) and chronic GvHD (HR = 0.50, P = 0.02) was significantly lower in the haplo-BM group compared with the UD-PB group. There was no significant difference between the study groups with respect to relapse incidence, nonrelapse mortality, leukemia-fee survival, overall survival, or GvHD-free and relapse-free survival.CONCLUSIONS: The use of a haplo donor with a BM graft resulted in a lower incidence of GvHD compared with a UD-PB stem cell graft in the setting of PTCy for patients with acute leukemia. However, differences in GvHD did not translate into a difference in survival outcomes. Based upon these data, UD-PB or haplo-BM should be considered equally acceptable sources for allo-HCT.",
author = "Arnon Nagler and Myriam Labopin and Bhagirathbhai Dholaria and Emanuele Angelucci and Boris Afanasyev and Cornelissen, {Jan J} and Simona Sica and Ellen Meijer and Fabio Ciceri and {Van Gorkom}, Gwendolyn and Nicolaus Kr{\"o}ger and Hans Martin and Pietro Pioltelli and Antonio Risitano and Jonathan Canaani and Savani, {Bipin N} and Jaime Sanz and Mohamad Mohty",
note = "{\textcopyright}2020 American Association for Cancer Research.",
year = "2021",
month = feb,
day = "1",
doi = "10.1158/1078-0432.CCR-20-2809",
language = "English",
volume = "27",
pages = "843--851",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia

AU - Nagler, Arnon

AU - Labopin, Myriam

AU - Dholaria, Bhagirathbhai

AU - Angelucci, Emanuele

AU - Afanasyev, Boris

AU - Cornelissen, Jan J

AU - Sica, Simona

AU - Meijer, Ellen

AU - Ciceri, Fabio

AU - Van Gorkom, Gwendolyn

AU - Kröger, Nicolaus

AU - Martin, Hans

AU - Pioltelli, Pietro

AU - Risitano, Antonio

AU - Canaani, Jonathan

AU - Savani, Bipin N

AU - Sanz, Jaime

AU - Mohty, Mohamad

N1 - ©2020 American Association for Cancer Research.

PY - 2021/2/1

Y1 - 2021/2/1

N2 - PURPOSE: Posttransplant cyclophosphamide (PTCy) is increasingly being utilized as a principle GvHD prophylaxis strategy in allogeneic hematopoietic cell transplantation (allo-HCT). A haploidentical (haplo) or matched unrelated donor (UD) is a valid option in the absence of a matched related donor.EXPERIMENTAL DESIGN: We compared the outcomes of patients with acute leukemia who underwent haplo bone marrow (haplo-BM, N = 401) versus UD mobilized peripheral blood stem cells (UD-PB, N = 192) transplantation in the setting of PTCy.RESULTS: The median follow-up duration was 36 months in the haplo-BM group and 16.6 months in the UD-PB group, respectively (P < 0.01). Myeloablative conditioning was used in 64.6% and 42.7% of haplo-BM and UD-PB patients, respectively (P < 0.01). Cumulative incidence of neutrophil engraftment at day 30 was 87% in haplo-BM versus 94% in UD-PB, respectively (P = 0.21). In the multivariate analysis, the risk of grade 2-4 acute GvHD (HR = 0.53, P = 0.01) and chronic GvHD (HR = 0.50, P = 0.02) was significantly lower in the haplo-BM group compared with the UD-PB group. There was no significant difference between the study groups with respect to relapse incidence, nonrelapse mortality, leukemia-fee survival, overall survival, or GvHD-free and relapse-free survival.CONCLUSIONS: The use of a haplo donor with a BM graft resulted in a lower incidence of GvHD compared with a UD-PB stem cell graft in the setting of PTCy for patients with acute leukemia. However, differences in GvHD did not translate into a difference in survival outcomes. Based upon these data, UD-PB or haplo-BM should be considered equally acceptable sources for allo-HCT.

AB - PURPOSE: Posttransplant cyclophosphamide (PTCy) is increasingly being utilized as a principle GvHD prophylaxis strategy in allogeneic hematopoietic cell transplantation (allo-HCT). A haploidentical (haplo) or matched unrelated donor (UD) is a valid option in the absence of a matched related donor.EXPERIMENTAL DESIGN: We compared the outcomes of patients with acute leukemia who underwent haplo bone marrow (haplo-BM, N = 401) versus UD mobilized peripheral blood stem cells (UD-PB, N = 192) transplantation in the setting of PTCy.RESULTS: The median follow-up duration was 36 months in the haplo-BM group and 16.6 months in the UD-PB group, respectively (P < 0.01). Myeloablative conditioning was used in 64.6% and 42.7% of haplo-BM and UD-PB patients, respectively (P < 0.01). Cumulative incidence of neutrophil engraftment at day 30 was 87% in haplo-BM versus 94% in UD-PB, respectively (P = 0.21). In the multivariate analysis, the risk of grade 2-4 acute GvHD (HR = 0.53, P = 0.01) and chronic GvHD (HR = 0.50, P = 0.02) was significantly lower in the haplo-BM group compared with the UD-PB group. There was no significant difference between the study groups with respect to relapse incidence, nonrelapse mortality, leukemia-fee survival, overall survival, or GvHD-free and relapse-free survival.CONCLUSIONS: The use of a haplo donor with a BM graft resulted in a lower incidence of GvHD compared with a UD-PB stem cell graft in the setting of PTCy for patients with acute leukemia. However, differences in GvHD did not translate into a difference in survival outcomes. Based upon these data, UD-PB or haplo-BM should be considered equally acceptable sources for allo-HCT.

U2 - 10.1158/1078-0432.CCR-20-2809

DO - 10.1158/1078-0432.CCR-20-2809

M3 - SCORING: Journal article

C2 - 33148668

VL - 27

SP - 843

EP - 851

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 3

ER -